The reduction in price target by Craig-Hallum could lead to a negative perception among investors, potentially causing a short-term decrease in the stock price of Accelerate Diagnostics. The Hold rating suggests that the analyst sees limited upside or downside potential, but the lowered price target indicates a revised, less optimistic valuation of the company.